BlossomHill Therapeutics (BLSM) News Today

BlossomHill Therapeutics, Inc. (NASDAQ: BLSM) shares have increased and are trading near their 52-week high, supported by a wave of new analyst coverage and a favorable price target from HC Wainwright.

• Positive Sentiment: HC Wainwright maintains a bullish outlook: The firm initiated research coverage and assigned a “Buy” rating with a $35 price target, implying meaningful upside from recent trading levels. Its estimates also project narrowing losses, from $3.71 per share in fiscal 2026 to $2.99 in fiscal 2027. HC Wainwright coverage
• Positive Sentiment: Broader institutional attention: Guggenheim, Leerink Partners, JPMorgan Chase and Lifesci Capital have also initiated or announced research coverage on BLSM. Expanded analyst coverage can improve investor awareness and potentially increase trading liquidity. Guggenheim coverage
• Positive Sentiment: Upcoming investor presentations: BlossomHill plans to present at the RAS-Targeted Drug Development Summit and the H.C. Wainwright Global Investment Conference, giving investors an opportunity to receive updates on its oncology pipeline and development strategy. BlossomHill investor presentations
• Neutral Sentiment: Zacks upgraded BLSM to “Hold.” The change indicates a more neutral stance rather than a strong sell signal, but it may temper the optimism created by the new “Buy” coverage. Zacks rating change
• Negative Sentiment: BlossomHill remains loss-making. HC Wainwright forecasts additional quarterly losses through 2027, including an estimated $3.71-per-share loss for fiscal 2026. The stock therefore remains dependent on clinical progress, future financing and eventual commercialization prospects.